SOURCE: Theravance, Inc.

Theravance, Inc.

February 03, 2010 16:05 ET

Theravance to Report Fourth Quarter and Full Year 2009 Financial Results on February 11, 2010

SOUTH SAN FRANCISCO, CA--(Marketwire - February 3, 2010) - Theravance, Inc. (NASDAQ: THRX) announced today that it will release financial results for the fourth quarter and full year ended December 31, 2009 after market close on Thursday, February 11, 2010.

An accompanying conference call will be held at 5:00 p.m. Eastern Standard Time. To participate in the live call by telephone, please dial 888-710-4013 from the U.S., or 913-312-0418 for international callers. Those interested in listening to the conference call live via the internet may do so by visiting the company's web site at To listen to the live call, please go to the web site 15 minutes prior to its start to register, download, and install any necessary audio software.

A replay of the conference call will be available on the company's web site for 30 days through March 13, 2010. An audio replay will also be available through 11:59 p.m. Eastern Standard Time on February 18, 2010 by dialing 888-203-1112 from the U.S., or 719-457-0820 for international callers, and entering confirmation code 2324359.

About Theravance

Theravance is a biopharmaceutical company with a pipeline of internally discovered product candidates. Theravance is focused on the discovery, development and commercialization of small molecule medicines across a number of therapeutic areas including respiratory disease, bacterial infections and gastrointestinal motility dysfunction. The company's key programs include: VIBATIV™ with Astellas Pharma Inc. and RELOVAIR™ and Bifunctional Muscarinic Antagonist-Beta2 Agonist (MABA) program with GlaxoSmithKline plc. By leveraging its proprietary insight of multivalency toward drug discovery, Theravance is pursuing a next generation strategy designed to discover superior medicines in areas of significant unmet medical need. For more information, please visit the company's web site at

THERAVANCE®, the Theravance logo, and MEDICINES THAT MAKE A DIFFERENCE® are registered trademarks of Theravance, Inc.

VIBATIV is a trademark of Astellas Pharma Inc.

RELOVAIR is a trademark of Glaxo Group Limited.

Contact Information

  • Contact Information:

    Michael W. Aguiar
    Senior Vice President and Chief Financial Officer
    Email Contact